BioHarvest Sciences (BHST)

The company operates through two main business lines. Its Products business focuses on science-based nutraceutical and wellness solutions that are manufactured and sold as dietary supplements, functional foods and beverages. These products are designed for consumer health markets where demand is driven by interest in plant-derived ingredients, evidence-based wellness and differentiated formulations.

BioHarvest’s second business line is its CDMO Services unit, which provides contract development and manufacturing capabilities. Through this segment, the company applies its technology and process expertise for partners in areas such as pharmaceuticals, cosmeceuticals, nutraceuticals and nutrition. The CDMO model gives BioHarvest a route to participate in third-party product development and manufacturing while leveraging the same underlying platform.

The company’s core distinction is its focus on growing valuable plant cells directly, rather than cultivating and harvesting full plants. This can be relevant in markets where active compounds are difficult to source consistently or where supply chains are exposed to agricultural variability.

For investors, BHST offers exposure to the intersection of biotechnology, consumer wellness and outsourced product development. Its performance depends on the commercial adoption of its nutraceutical products, the ability to scale its patented platform, and the success of partnerships or service contracts in the broader health, nutrition and life sciences markets.